inhibitors – Talk Bio

Actionable Insights Powered by AI

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

2 weeks ago talkbio0Tagged Bimzelx, Clinical Trials, Cosentyx, drug approval outlook, drug market, Hidradenitis Suppurativa, inhibitors, Interleukin-17, MoonLake Immunotherapeutics, Placebos, Response process, sonelokimab

MoonLake Immunotherapeutics; Sonelokimab; hidradenitis suppurativa; Phase 3 trial; clinical trial results; biotech shares; placebo response; drug approval outlook; IL-17 inhibitors; Bimzelx; Cosentyx; drug market potential

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

4 weeks ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic

7 months ago talkbio0Tagged Acute onset pain, biotherapeutics, Chronic pain, Clinical Trials, inhibitors, Latigo, non-opioid pain drugs, SCN10A gene, Series B

Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

7 months ago talkbio0Tagged Biochemical Pathway, BridgeBio, cancer pipeline, Helix (Snails), inhibitors, K-ras Oncogene, KRAS, Merger, Neoplasms, PI3 K pathway, ras Oncogene, SPAC

BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

9 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors

10 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A, Hemophilia B, inhibitors, once-daily, Prophylactic treatment, subcutaneous, United States Food and Drug Administration

Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment

Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors

10 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A and B, inhibitors, Nordisk, once-daily, Prophylactic treatment, United States Food and Drug Administration

Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab

FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns

10 months ago talkbio0Tagged Andexxa, Approved, AstraZeneca, concerns, F10 wt Allele, Hemorrhage, inhibitors, reversal agent, Safety, United States Food and Drug Administration

Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors

NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations

11 months ago talkbio0Tagged CETP, cholesterol-lowering drugs, Expectations, inhibitors, investor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 trials

NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction

Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm

12 months ago talkbio0Tagged biopharmaceutical industry, Combined Modality Therapy, inhibitors, Malignant Neoplasms, PD-1/PD-L1, Public Listing, Vascular Endothelial Growth Factor A

PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing